(Q38882536)

English

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

scientific article published on 5 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial (English)

1 reference

Europe PubMed Central

7 September 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

18

1 reference

Europe PubMed Central

7 September 2017

4

object named as

Axel Le Cesne

0 references

object named as

Olivier Mir

1

0 references

Isabelle Ray-Coquard

8

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

7 September 2017

Nicolas Isambert

16

object named as

Nicolas Isambert

1 reference

Europe PubMed Central

7 September 2017

Florence Duffaud

14

object named as

Florence Duffaud

1 reference

Europe PubMed Central

7 September 2017

François Bertucci

15

object named as

François Bertucci

1 reference

Europe PubMed Central

7 September 2017

Emmanuelle Bompas

6

object named as

Emmanuelle Bompas

1 reference

Europe PubMed Central

7 September 2017

3

object named as

Maud Toulmonde

1 reference

Europe PubMed Central

7 September 2017

Olivier Bouché

12

object named as

Olivier Bouché

1 reference

Europe PubMed Central

7 September 2017

2

object named as

Claire Cropet

1 reference

Europe PubMed Central

7 September 2017

Mathieu Molimard

5

object named as

Mathieu Molimard

1 reference

Europe PubMed Central

7 September 2017

Philippe Alexandre Cassier

7

object named as

Philippe Cassier

1 reference

Europe PubMed Central

7 September 2017

10

object named as

Antoine Adenis

1 reference

Europe PubMed Central

7 September 2017

19

object named as

David Pérol

1 reference

Europe PubMed Central

7 September 2017

author name string

Maria Rios

9

1 reference

Europe PubMed Central

7 September 2017

Antoine Italiano

11

1 reference

Europe PubMed Central

7 September 2017

Emmanuelle Chauzit

13

1 reference

Europe PubMed Central

7 September 2017

Julien Gautier

17

1 reference

Europe PubMed Central

7 September 2017

PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)

20

1 reference

Europe PubMed Central

7 September 2017

publication date

5 April 2016

1 reference

Europe PubMed Central

7 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

7 September 2017

17

1 reference

Europe PubMed Central

7 September 2017

5

1 reference

Europe PubMed Central

7 September 2017

632-641

1 reference

Europe PubMed Central

7 September 2017

Advances in the treatment of gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal stromal tumors: pathology and prognosis at different sites

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience to date with nilotinib in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib and the treatment palette for soft-tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib: Clinical development of a potent anti-angiogenic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900075-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)00075-9

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38882536&oldid=1835243990"